Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BCHT Tdap Vaccine in People Aged 10 Years and Older
NCT07492303Phase 1Not yet recruiting
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of tdap vaccine in pertussis, diphtheria and Tetanus (3 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Adverse Events at 30 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tdap vaccine
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on NCT07492303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492303.